Physician profile
James J Tess
NPI 1629016803
$1,607.78
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $278 · 2021: $274 · 2022: $203 · 2023: $200 · 2024: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $494.34 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $439.07 | 2021-2024 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.78 | 2019-2020 | |
| Abbott Laboratories | $72.86 | 2022-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $67.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $58.24 | 2019-2020 | |
| Allergan, INC. | $56.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $45.75 | 2019-2020 | |
| Ibsa Pharma INC. | $35.75 | 2019-2020 | |
| Glaxosmithkline, LLC. | $32.68 | 2019-2022 | |
| Lilly USA, LLC | $27.01 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.75 | 2020 | |
| Pfizer INC. | $15.08 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.83 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.16 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.